Services
Novel biomarker development
We go beyond the measurements by developing, validating, and offering innovative biomarkers that re-imagine how to monitor disease progression throughout a joint.
The FDA Biomarker Qualification Program has accepted a qualification plan for two of our composite biomarkers, making them the first OA-related biomarkers to achieve this milestone.
Cartilage damage index
Instead of traditional segmentation strategies, we focus on the most informative anatomic regions to create highly sensitive metrics of cartilage change.
Bone marrow lesion volume
Effusion-synovitis volume
